Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2015 16:05 ET | Source: Relypsa, Inc.

Relypsa Announces Third Quarter 2015 Financial Results

REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today reported financial results for the quarter ended September 30, 2015...
November 03, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa to Present at Two Upcoming Conferences

REDWOOD CITY, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that the company will present at two upcoming investor conferences in November 2015. John A....
October 29, 2015 16:30 ET | Source: Relypsa, Inc.

Relypsa Announces Data for Veltassa (patiromer) to be Presented at ASN Kidney Week 2015

OPAL-HK sub-group analysis in hyperkalemic chronic kidney disease (CKD) patients age 65 or older will be featured in oral presentation Poster presentation will highlight data from OPAL-HK...
October 21, 2015 20:34 ET | Source: Relypsa, Inc.

RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA

First new medicine for the treatment of hyperkalemia, or high blood potassium levels, in more than 50 years Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure...
October 19, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on October 15, 2015, the compensation committee of the...
October 13, 2015 16:30 ET | Source: Relypsa, Inc.

European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS

Pre-specified sub-group analysis from OPAL-HK trial of hyperkalemic chronic kidney disease (CKD) patients with heart failure receiving renin angiotensin aldosterone system (RAAS) inhibitor therapy...
October 02, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on October 1, 2015, the compensation committee of the company's...
September 21, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 15, 2015, the compensation committee of the...
September 16, 2015 16:43 ET | Source: Relypsa, Inc.

Relypsa Announces Publication of Patiromer FOS Onset-of-Action Study in Kidney International

Study to establish onset of action, conducted in diet-controlled patients with chronic kidney disease and moderate-to-severe hyperkalemia, taking RAAS inhibitor therapy Patiromer FOS...
September 04, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 1, 2015, the compensation committee of the company's...